Plant Cell Culture Media Patents: Top Companies & Trends 2026
- Top 5 filers hold 48.0% of the field. 3,218 of 6,699 records in scope sit with just five assignees, so freedom-to-operate searches concentrate fast around a small set of names.
- Filing has held steady, not fallen. 2021 to 2024 (the last complete year) moved from 118 to 121 filings, +3% — a plateau, not a decline, once the 18-month publication lag is accounted for.
- Seed and trait giants dominate, not media specialists. The heaviest classes are C12N (86.7%) and A01H (85.0%), meaning most claims sit on genetic engineering and plant breeding rather than on culture medium chemistry itself.
Filing growth compares 2021 (118 records) with 2024 (121) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 6,699 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Plant cell culture media formulation sits at the intersection of tissue culture technique and molecular plant biology: amino acid supplementation, growth factor dosing, lipid supplements, osmolality and glucose control, and serum-replacement strategies used to grow plant cells, calli or suspensions outside the whole organism. The scope here pulls records that combine those media-formulation terms with core plant cell culture and plant tissue culture language, filtered to C12N5/04, A01H4/00 and C12M3/00 — the classification core for plant cell/tissue culture and the apparatus used to grow it.
6,699 records fall inside this scope across the 2015–2026 window, with the data cut off at 2026-07-31. Because publication lags filing by roughly 18 months, the most recent one to two years in any trend chart will read lower than the eventual filed total once those applications publish.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Trend and technology composition
Two views of the same 6,699 records: how filing volume has moved year over year, and which IPC subclasses carry the claims.
Filing trend: a plateau, not a decline
Annual filings peaked in 2017 at 265 and have since settled into a lower, comparatively stable band. Using only the years that can be treated as complete, 2021 (118) to 2024 (121) moved +3% — essentially flat. Years after 2024 will continue to fill in as publications catch up, so treat any apparent drop in 2025-2026 as an artefact of lag, not a real fall-off in filing activity.
Technology composition: genetics-heavy, media-light
C12N (microorganisms and genetic engineering) and A01H (new plants and plant breeding) each cover more than 85% of the 6,699 records in scope, confirming that most of this corpus is filed as trait or transformation work that happens to touch culture media, not as media-chemistry patents in their own right. Downstream classes are thinner: C12Q (measuring/testing, 19.8%), C07K (peptides and proteins, 19.6%), A23L (foods, 16.5%), A23J (food proteins, 9.5%), A23K (animal feed, 8.8%) and C07H (sugars and nucleic acids, 8.4%). A record can carry several classes, so these shares add to more than 100%.
Shares are the percentage of the 6,699 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Plant Cell Culture Media Formulation with Eureka
This page is one run against one query. Ask Eureka your own question about plant cell culture media formulation and every answer comes back with the patent numbers behind it.
Try EurekaHighest-cited records and a recent filing
EP3283092B1 — Cell-free plant cell culture suspension supernatant with rejuvenation and/or wound-healing activity on skin cells
Filed by VYTRUS BIOTECH, S.L. and published 2026-04-29, this record describes a cell-free supernatant derived from plant cell suspension culture, claimed for rejuvenation and wound-healing effects on skin cells — a cosmetic/dermal application rather than an agricultural trait claim.Original title is in German in the source record; rendered here in English for readability.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | EP0392225A2 | Disease-resistant transgenic plants | 3,053 |
| 2 | US6040498A | Genetically engineered duckweed | 2,580 |
| 3 | US5633435A | Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases | 2,376 |
| 4 | US5608149A | Enhanced starch biosynthesis in tomatoes | 1,760 |
| 5 | US4761373A | Herbicide resistance in plants | 1,693 |
| 6 | US5561236A | Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA f… | 1,594 |
| 7 | US6982367B2 | Soybean cultivar 0509244 | 1,363 |
| 8 | US6960707B2 | Soybean cultivar S010364 | 1,354 |
| 9 | US6969787B2 | Soybean cultivar S030160 | 1,352 |
| 10 | US6979760B2 | Soybean cultivar S030010 | 1,342 |
Citation counts favour older filings inside a searched corpus — treat them as a signal of influence on later work, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about this field
Three read-outs from the dataset that matter for anyone deciding where to file or search for prior art.
The field is top-heavy
3,218 of the 6,699 records in scope belong to just five assignees, and the top 10 combined reach 61.2% (4,101 records). A freedom-to-operate review in this space will spend most of its time on a short list of names before it ever reaches the long tail.
Flat, not falling
After the 2017 peak of 265, annual filings settled lower but have not continued to decline — the last complete comparison years show growth, however modest. Read 2025-2026 figures as undercounts still catching up to publication, not as a cooling trend.
Genetics dominates the corpus
The two largest IPC subclasses, C12N and A01H, each cover more than four in five records, meaning the bulk of this landscape is trait and transformation IP that happens to reference culture media conditions, not standalone media-chemistry patents.
US and Canada lead filing venues
The United States (2,839) and Canada (1,579) receive far more filings than Europe (515), Australia (475), WIPO/PCT (418) or Japan (171), pointing to North America as the primary commercial battleground for this technology.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to plant cell culture media formulation, with the prior art for and against each one.
Who holds the ground, and what is still open
The ranked leaders are drawn from the 100 companies the data endpoint returns for this scope — not a curated top-50 or top-100 list, simply the full ranking available.
One filer sets the pace
The leading assignee holds 1,127 of the 6,699 records in scope, well ahead of fifth place at 291 and tenth place at 142 — a steep drop-off that concentrates most of the field's IP in a handful of long-running agricultural biotech portfolios.
Alliance filing is concentrated
Ten co-assignee pairs appear in this dataset, and the strongest single pairing accounts for 373 shared records — evidence of a long-standing collaborative filing relationship between two of the leading agricultural biotech portfolios rather than fragmented joint ventures.
Leaders show zero latest-year filings
Several of the highest-ranked assignees show zero filings in the latest tracked year, each a -100% year-over-year change. Given the roughly 18-month publication lag, this reads as a reporting gap rather than an actual halt in filing activity by these portfolios.
| Assignee | Recent year | YoY |
|---|---|---|
| Pioneer Hi-Bred International, Inc. | 0 | -100% |
| Monsanto Technology LLC | 0 | -100% |
| STINE SEED FARM INC | 0 | — |
| Syngenta Participations AG | 0 | — |
| Dow AgroSciences LLC | 0 | — |
| M S Tech LLC | 0 | — |
| The Regents of the University of California | 0 | — |
| Agrigenetics, Inc. | 0 | — |
Where to take this from here
The landscape points to where claim density sits and where it thins — the next step is testing a specific formulation or claim against that picture.
Check freedom-to-operate against the top-heavy leaders
With 61.2% of records held by the top 10 assignees, a targeted clearance search against that short list will cover most of the risk before touching the long tail.
Run a clearance search in EurekaProbe the under-claimed media-specific branches
Osmolality control, lipid supplementation and serum-replacement formulations sit well below the C12N/A01H density — worth a focused novelty check before drafting claims there.
Explore white space in EurekaCommon questions on this landscape
One assignee leads with 1,127 of the 6,699 records in scope, a wide margin over the fifth-ranked filer at 291 and the tenth at 142. The top 5 assignees together hold 48.0% of all records, and the top 10 hold 61.2%. This is a top-heavy field: most of the enforceable IP sits with a small number of long-established agricultural biotech portfolios rather than being spread evenly across many smaller filers.
Filing peaked in 2017 at 265 records and settled lower afterward, but it has not continued to decline. Comparing the last two years that can be treated as complete, 2021 (118) and 2024 (121), filings rose 3%. Because patent publication lags filing by roughly 18 months, the lower counts shown for 2025 and 2026 in any trend chart understate the true filing volume for those years and should not be read as a slowdown.
EP3283092B1, filed by VYTRUS BIOTECH, S.L. and published 2026-04-29, covers a cell-free supernatant derived from plant cell culture suspension, claimed for rejuvenation and wound-healing activity on skin cells. It is a cosmetic and dermal-application patent built on plant cell culture technique rather than an agricultural trait or seed patent, which distinguishes it from most of the highest-cited records in this dataset.
C12N (microorganisms and genetic engineering) and A01H (new plants and plant breeding) dominate, covering 86.7% and 85.0% of the 6,699 records respectively. Downstream application classes are much smaller: C12Q (enzyme/DNA testing) and C07K (peptides and proteins) each sit near 19-20%, while A23L, A23J, A23K and C07H range from roughly 8% to 16.5%. This means most patents in scope are transformation or trait patents that reference culture media conditions, not dedicated media-formulation chemistry patents.
The smallest IPC shares in this dataset point to the least-claimed branches: C07H (sugars and nucleic acids, 8.4%) and A23K (animal feed, 8.8%) trail well behind the dominant genetics classes. Within media formulation specifically, osmolality control, lipid-supplemented callus induction, serum-replacement formulations and glucose-control feeding strategies are named sub-areas worth a targeted novelty check, since the dense C12N/A01H coverage does not extend evenly into these more specific formulation techniques.
Research Plant Cell Culture Media Formulation in depth with Eureka
Go past this page: query the whole plant cell culture media formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.